MIMEDX GROUP, INC.
Close on Oct 19, 2026
- Market cap
- $647.35M
- P/E (TTM)
- 109.5
- Dividend yield
- –
Earnings
Next report expected Oct 28, 2026, after market close (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Jul 29, 2026 | After market close | $64.00M | – | – |
| Q1 FY2026 Ended Mar 31, 2026 | Apr 29, 2026 | After market close | $59.00M | $-0.07 | $-0.05 |
| Q4 FY2025 Ended Dec 31, 2025 | Feb 25, 2026 | After market close | $118.00M | $0.10 | $0.14 |
| Q3 FY2025 Ended Sep 30, 2025 | Oct 29, 2025 | After market close | – | – | $0.15 |
| Q2 FY2025 Ended Jun 30, 2025 | Jul 30, 2025 | After market close | $99.00M | $0.06 | $0.10 |
| Q1 FY2025 Ended Mar 31, 2025 | Apr 30, 2025 | After market close | $88.00M | – | – |
| Q4 FY2024 Ended Dec 31, 2024 | Feb 26, 2025 | After market close | $93.00M | $0.05 | $0.07 |
| Q3 FY2024 Ended Sep 30, 2024 | Oct 30, 2024 | After market close | $84.00M | $0.05 | $0.07 |
| Q2 FY2024 Ended Jun 30, 2024 | Jul 31, 2024 | After market close | – | – | – |
| Q1 FY2024 Ended Mar 31, 2024 | Apr 30, 2024 | After market close | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Feb 28, 2024 | After market close | – | – | – |
Company guidance
Outlook given with results on Jul 29, 2026, compared with the previous outlook
| Measure | Period | Guidance | vs. prior |
|---|---|---|---|
| net sales | 2026 | $260.00M to $290.00M | Maintained |
Figures and the sentence they come from are taken from the company's earnings release. Hover a measure to read the source sentence.
Press releases
Announcements Mimedx filed with the SEC
MIMEDX Announces Second Quarter 2026 Operating & Financial Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Investor Conference Call July 29, 2026
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Sanara MedTech Acquisition Details | 6 |
Results of operations · Regulation FD disclosure · EX-99.3 to Form 8-K
MIMEDX to Acquire Sanara MedTech
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
MIMEDX to Acquire Sanara MedTech July 29, 2026
Material agreement · Regulation FD disclosure · EX-99.2 to Form 8-K
EX-99.1 to Form 8-K
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Q1:26 Financial Results Conference Call April 29, 2026
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Forging into Several Subspecialties with Our Surgical Portfolio Opportunities across a range of procedures and subspecialties | 8 |
Results of operations · Regulation FD disclosure · EX-99.3 to Form 8-K
EX-99.1 to Form 8-K
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Q4 & FY 2025 Financial Results Conference Call February 25, 2026
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Distribution Agreements Significantly Diversify Wound & Surgical Offering | 15 | In the last year, we have added several adjacent products to our Wound & Surgical portfolio through distribution and co- promote agreements, including:
Results of operations · Regulation FD disclosure · EX-99.3 to Form 8-K
Highlights from Our Expanding Product Portfolio 10Investor Presentation – October 2025 Innovative Wound Products Growing Surgical Offering Expanding into Xenografts
Results of operations · Regulation FD disclosure · EX-99.4 to Form 8-K
Financial Results Conference Call October 29, 2025 Q3:2025
Results of operations · Regulation FD disclosure · EX-99.5 to Form 8-K
EX-99.6 to Form 8-K
Results of operations · Regulation FD disclosure · EX-99.6 to Form 8-K
Cantor Global Healthcare Conference September 3, 2025 Investor Presentation
Regulation FD disclosure · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Financial Results Conference Call July 30, 2025 Q2:2025
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Highlights from Our Expanding Product Portfolio 9Investor Presentation – August 2025 Innovative Wound Products Growing Surgical Offering Expanding into Xenografts
Results of operations · Regulation FD disclosure · EX-99.3 to Form 8-K
BofA Securities 2025 Health Care Conference May 2025 Investor Presentation
Regulation FD disclosure · EX-99.1 to Form 8-K
MIMEDX Announces First Quarter 2025 Operating and Financial Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Financial Results Conference Call April 30, 2025 Q1 2025
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Highlights from Our Expanding Product Portfolio 9Investor Presentation – May 2025 Flagship Wound Allograft Growing Surgical Offering Expanding into Xenografts
Results of operations · Regulation FD disclosure · EX-99.3 to Form 8-K
Highlights from Our Expanding Product Portfolio 10Investor Presentation – February 2025 Flagship Wound Allograft Growing Surgical Offering Expanding into Xenografts
Regulation FD disclosure · EX-99.1 to Form 8-K
MIMEDX Announces Fourth Quarter and Full Year 2024 Operating and Financial Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Financial Results Conference Call February 26, 2025 Q4 & Full Year 2024
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Disclaimer & Cautionary Statements This presentation includes
Regulation FD disclosure · EX-99.1 to Form 8-K
MIMEDX Announces Third Quarter 2024 Operating and Financial Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Disclaimer & Cautionary Statements This presentation includes
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Disclaimer & Cautionary Statements This presentation includes
Results of operations · Regulation FD disclosure · EX-99.3 to Form 8-K
MIMEDX Announces Second Quarter 2024 Operating and Financial Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Disclaimer & Cautionary Statements This presentation includes
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Disclaimer & Cautionary Statements This presentation includes
Results of operations · Regulation FD disclosure · EX-99.3 to Form 8-K
MIMEDX Announces First Quarter 2024 Operating and Financial
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Disclaimer & Cautionary Statements This presentation includes
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Disclaimer & Cautionary Statements This presentation includes
Results of operations · Regulation FD disclosure · EX-99.3 to Form 8-K
MIMEDX Provides Update on AXIOFILL® Request for Designation (“RFD”) from FDA
Regulation FD disclosure · EX-99 to Form 8-K
MIMEDX Announces Fourth Quarter and Full Year 2023 Operating and Financial Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K